- Amid rising concerns over the potential development of resistance to Pfizer Inc's PFE COVID-19 pill Paxlovid, the company has declined to supply researchers with the antiviral for use in combination studies, according to a Bloomberg report.
- Researchers say that Paxlovid combined with other drugs might stave off resistance.
- Pfizer hasn't started any combination trials in people, and a review of the clinicaltrials.gov database shows no outpatient combination studies with Paxlovid.
- Efforts to study combinations have been slowed by the extra red tape around emergency use authorizations, according to Carl Dieffenbach, leader of the Biden effort to develop antivirals for Covid and future pandemic threats.
- The appearance of resistance to Paxlovid "is likely just a matter of time," according to Derek Lowe, a medicinal chemist and industry blogger who said he's surprised that combination trials aren't already underway with Paxlovid. "From where I stand it looks like a natural thing to try."
- Pfizer's reluctance to share its antiviral with collaborators has been "disturbing," said Reshma Ramachandran, a postdoctoral fellow in Yale University's National Clinician Scholars Program.
- "It's all very puzzling," she said. "It makes me wonder what's going on."
- Price Action: PFE shares are up 0.06% at $50.43 during the market session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.